Tae Sung

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

Wenyue Hu, Tae Sung, Bart Jessen et al. · Clinical Cancer Research · 2015 · 167 citations

Medicine, Oncology, Pharmacology +15

Lysosomal adaptation: How cells respond to lysosomotropic compounds

Shuyan Lu, Tae Sung, Nianwei Lin et al. · PLoS ONE · 2017 · 156 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Cynthia L. Palmer, Britton Boras, Bernadette Pascual et al. · Cancer Cell · 2025 · 51 citations · Full text

Medicine, Oncology, Pharmacology +13

Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology

Stéphane Thibault, Wenyue Hu, Brad Hirakawa et al. · Molecular Cancer Therapeutics · 2018 · 33 citations

Medicine, Oncology, Pharmacology +14

Use of the dTAG system <i>in vivo</i> to degrade CDK2 and CDK5 in adult mice and explore potential safety liabilities

Paul Yenerall, Tae Sung, Kiran Palyada et al. · Toxicological Sciences · 2023 · 15 citations · Full text

Life Sciences, Molecular Biology, Toxicology +16